Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 4, 2011, Pages 853-869

  Lebbadi, Meryem ^a,b   Julien, Carl ^a,b   Phivilay, Alix ^a,b   Tremblay, Cyntia ^a,b   Emond, Vincent ^a,b   Kang, Jing X ^c   Calon, Frédéric ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer disease; docosahexaenoic acids; n 3 fatty acid desaturase; n 3 polyunsaturated fatty acid; transgenic mice

Indexed keywords

ACYL COENZYME A DESATURASE; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIN DEPENDENT KINASE 5; DOCOSAHEXAENOIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; POLYUNSATURATED FATTY ACID; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; BRAIN; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENE; TRANSGENIC MOUSE;

EID: 84455193348     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111010     Document Type: Article

References (126)

1. Fedorova I, Salem N Jr (2006) Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot Essent Fatty Acids 75, 271-289 (Pubitemid 44444990)
2. Carrie I, Smirnova M, Clement M, De JD, Frances H, Bourre JM (2002) Docosahexaenoic acid-rich phospholipid supplementation: effect on behavior, learning ability, and retinal function in control and n-3 polyunsaturated fatty acid deficient old mice. Nutr Neurosci 5, 43-52 (Pubitemid 34228993)
3. Hashimoto M, Hossain S, Shimada T, Shido O (2006) Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 33, 934-939 (Pubitemid 44427316)
4. Cao D,Kevala K,KimJ,MoonHS, Jun SB, Lovinger D,Kim HY (2009) Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem 111, 510-521
5. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimers disease mouse model. Neuron 43, 633-645 (Pubitemid 39179724)
6. Calon F, Cole G (2007) Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 77, 287-293 (Pubitemid 350198857)
7. Lukiw WJ, BazanNG(2008) Docosahexaenoic acid and the aging brain. J Nutr 138, 2510-2514
8. Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P (2009) Fish, docosahexaenoic acid and Alzheimers disease. Prog Lipid Res 48, 239-256
9. Julien C, Berthiaume L, Hadj-Tahar A, Rajput AH, Bedard PJ, Di Paolo T, Julien P, Calon F (2006) Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int 48, 404-414 (Pubitemid 43327280)
10. Salem N Jr, Hullin F, Yoffe AM, Karanian JW, Kim HY (1989) Fatty acid and phospholipid species composition of rat tissues after a fish oil diet. Adv Prostaglandin Thromboxane Leukot Res 19, 618-622
11. Jones CR, Arai T, Rapoport SI (1997) Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem Res 22, 663-670 (Pubitemid 27242240)
12. Breckenridge WC, Morgan IG, Zanetta JP, Vincendon G (1973) Adult rat brain synaptic vesicles, II. Lipid composition. Biochim Biophys Acta 320, 681-686
13. Salem N Jr, Litman B, Kim HY, Gawrisch K (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36, 945-959 (Pubitemid 33065196)
14. Samieri C, Feart C, Letenneur L, Dartigues JF, Peres K, Auriacombe S, Peuchant E, Delcourt C, Barberger-Gateau P (2008) Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 88, 714-721
15. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ,Wilson PW,Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63, 1545-1550 (Pubitemid 44748796)
16. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH (2000) Fatty acid analysis of blood plasma of patients with Alzheimers disease, other types of dementia, and cognitive impairment. Lipids 35, 1305-1312 (Pubitemid 32064179)
17. Pasinetti GM, Zhao Z, QinW, Ho L, ShrishailamY, MacgroganD, RessmannW, Humala N, Liu X, Romero C, Stetka B, Chen L, Ksiezak-Reding H, Wang J (2007) Caloric intake and Alzheimers disease. Experimental approaches and therapeutic implications. Interdiscip Top Gerontol 35, 159-175
18. Calon F (2006) Nonpatentable drugs and the cost of our ignorance. CMAJ 174, 483-484
19. Parrott MD, Greenwood CE (2007) Dietary influences on cognitive function with aging: from high-fat diets to healthful eating. Ann N Y Acad Sci 1114, 389-397 (Pubitemid 350070395)
20. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimers disease: a case-control study. Br J Nutr 89, 483-489 (Pubitemid 36582118)
21. Heude B, Ducimetiere P, Berr C (2003) Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA study. Am J Clin Nutr 77, 803-808
22. Kotani S, Sakaguchi E,Warashina S, Matsukawa N, Ishikura Y, KisoY, Sakakibara M,Yoshimoto T, Guo J,Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159-164 (Pubitemid 44374788)
23. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The effects of omega-fatty acids monotherapy in Alzheimers disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32, 1538-1544
24. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 1402-1408 (Pubitemid 44547551)
25. Quinn CC, Gruber-Baldini AL, Port CL, May C, Stuart B, Hebel JR, Zimmerman S, Burton L, Zuckerman IH, Fahlman C, Magaziner J (2009) The role of nursing home admission and dementia status on care for diabetes mellitus. J Am Geriatr Soc 57, 1628-1633
26. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, StedmanM(2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 6, 456-464
27. Fotuhi M, Hachinski V, Kivipelto M, Whitehouse P. (2009) Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 73, 1607; author reply 1607-1608
28. Boston PF, Bennett A, Horrobin DF, Bennett CN (2004) Ethyl-EPA in Alzheimers disease-a pilot study. Prostaglandins Leukot Essent Fatty Acids 71, 341-346 (Pubitemid 39233559)
29. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304, 1903-1911
30. Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P, Calon F (2010) High-fat diet aggravates amyloidbeta and tau pathologies in the 3×Tg-AD mouse model. Neurobiol Aging 31, 1516-1531
31. Calon F, Julien C, Lebbadi M,Tremblay C, EmondV(2010). Manipulation of dietary fatty acids: Impact on neuropathological markers of AD in transgenic models. In Recent Advances on Nutrition and the Prevention of Alzheimers Disease, Ramassamy S, Bastianetto C (eds). India, pp. 97- 108
32. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimers disease. Eur J Neurosci 22, 617-626 (Pubitemid 41192272)
33. Perez SE, Berg BM, Moore KA, He B, Counts SE, Fritz JJ, Hu YS, Lazarov O, Lah JJ, Mufson EJ (2010) DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res 88, 1026-1040
34. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33, 482-498
35. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25, 3032-3040 (Pubitemid 40463537)
36. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23, 563-572 (Pubitemid 44234092)
37. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, Shytle RD, Tan J (2010) Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 471, 134-138
38. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, LaFerla FM (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27, 4385-4395 (Pubitemid 46640724)
39. Phivilay A, Julien C, Tremblay C, Berthiaume L, Julien P, Giguere Y, Calon F (2009) High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3×Tg- AD model of Alzheimers disease. Neuroscience 159, 296-307
40. Arsenault D, Julien C, Tremblay C, Calon F (2011) DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3×Tg-AD mice. PLoS One 6, e17397
41. Florent S, Malaplate-Armand C, Youssef I, Kriem B, Koziel V, Escanye MC, Fifre A, Sponne I, Leininger-Muller B, Olivier JL, Pillot T, Oster T (2006) Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloidbeta oligomers. J Neurochem 96, 385-395
42. Cole GM,MaQL, Frautschy SA(2009) Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 81, 213-221
43. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089
44. Sahlin C, Pettersson FE, Nilsson LN, Lannfelt L, JohanssonAS(2007) Docosahexaenoic acid stimulates nonamyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimers disease. Eur J Neurosci 26, 882-889 (Pubitemid 47274614)
45. Calder PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77, 327-335 (Pubitemid 350198856)
46. Mukherjee PK, Chawla A, Loayza MS, Bazan NG (2007) Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot Essent Fatty Acids 77, 233-238 (Pubitemid 350198868)
47. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG (2011) Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-and PPARgamma-mediated mechanisms in Alzheimers disease models. PLoS One 6, e15816
48. Michael-Titus AT (2007) Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fatty Acids 77, 295-300 (Pubitemid 350198867)
49. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y, Oka J, Shido O (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimers disease model rats. J Neurochem 81, 1084-1091 (Pubitemid 34809291)
50. Kim HY (2007) Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem 282, 18661-18665
51. Kang JX,Wang J,Wu L, Kang ZB (2004) Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427, 504 (Pubitemid 38209102)
52. Warude D, Joshi K, Harsulkar A (2006) Polyunsaturated fatty acids: biotechnology. Crit Rev Biotechnol 26, 83-93 (Pubitemid 43995261)
53. Orr SK, Tong JY, Kang JX, Ma DW, Bazinet RP (2010) The fat-1 mouse has brain docosahexaenoic acid levels achievable through fish oil feeding. Neurochem Res 35, 811-819
54. Bousquet M, Calon F, Cicchetti F (2011) Impact of omega-fatty acids in Parkinsons disease. Ageing Res Rev 10, 453-463
55. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimers disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421 (Pubitemid 36937044)
56. Shaikh NA, Downar E (1981) Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res 49, 316-325 (Pubitemid 11053292)
57. Lepage G, Roy CC (1986) Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27, 114-120 (Pubitemid 16045295)
58. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J (2010) GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol 223, 322-325
59. Gomez de Barreda E, Perez M, Gomez Ramos P, de Cristobal J, Martin-Maestro P, Moran A, Dawson HN, Vitek MP, Lucas JJ, Hernandez F, Avila J (2010) Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis 37, 622-629
60. Maccioni RB, Otth C, Concha II, Munoz JP (2001) The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimers pathology. Eur J Biochem 268, 1518-1527 (Pubitemid 32862683)
61. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J,Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565 (Pubitemid 36645031)
62. Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M, Seubert P (1996) Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulindependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J 316(Pt 2), 655-660 (Pubitemid 26182167)
63. MonacoEA, 3rd (2004) Recent evidence regarding a role for Cdk5 dysregulation in Alzheimers disease. Curr Alzheimer Res 1, 33-38
64. Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimers disease brains. FEBS Lett 523, 58-62 (Pubitemid 34786058)
65. Tian Q, Wang J (2002) Role of serine/threonine protein phosphatase in Alzheimers disease. Neurosignals 11, 262-269 (Pubitemid 37494393)
66. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimers disease. J Biol Chem 275, 5535-5544 (Pubitemid 30115189)
67. Kondo M, Shiono M, Itoh G, TakeiN, Matsushima T, Maeda M, Taru H, Hata S, Yamamoto T, Saito Y, Suzuki T (2010) Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. Mol Neurodegene 5, 35
68. LeeGD,Aruna JH, BarrettPM,Lei DL, IngramDK,Mouton PR (2005) Stereological analysis of microvascular parameters in a double transgenic model of Alzheimers disease. Brain Res Bull 65, 317-322 (Pubitemid 41057801)
69. Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y,Wiesner A, Schonrock N, Ittner LM (2007) A decade of tau transgenic animal models and beyond. Brain Pathol 17, 91-103
70. McGowan E, Eriksen J, HuttonM(2006) A decade of modeling Alzheimers disease in transgenic mice. Trends Genet 22, 281-289
71. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimers disease. Neurobiol Aging 24, 1063-1070 (Pubitemid 37487883)
72. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281, 39413-39423 (Pubitemid 46041901)
73. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimers disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688 (Pubitemid 40320703)
74. Hardy J (2009) The amyloid hypothesis for Alzheimers disease: a critical reappraisal. J Neurochem 110, 1129-1134
75. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27, 686-695
76. Scheuner D, Eckman C, JensenM,Song X, CitronM,Suzuki N, Bird TD, Hardy J, Hutton M, KukullW, Larson E, Levy- Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Nat Med 2, 864-870 (Pubitemid 26296755)
77. Citron M,WestawayD, XiaW, Carlson G, DiehlT, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997) Mutant presenilins of Alzheimers disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3, 67-72 (Pubitemid 27019143)
78. Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F (2007) Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimers disease. J Alzheimers Dis 12, 377-390
79. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577 (Pubitemid 30161512)
80. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14
81. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61, 378-384 (Pubitemid 38327357)
82. Gotz J, Ittner LM (2008) Animal models of Alzheimers disease and frontotemporal dementia. Nat Rev Neurosci 9, 532-544 (Pubitemid 351873467)
83. Morrissette DA, Parachikova A, Green KN, LaFerla FM (2009) Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem 284, 6033-6037
84. Salloway S, Mintzer J, Weiner MF, Cummings JL (2008) Disease-modifying therapies in Alzheimers disease. Alzheimers Dement 4, 65-79
85. Golde TE, Petrucelli L, Lewis J (2009) Targeting Abeta and tau in Alzheimers disease, an early interim report. Exp Neurol 223, 252-266
86. Selkoe DJ (2008) Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113
87. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T,Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimers disease. Am J Pathol 155, 853-862 (Pubitemid 29426831)
88. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimers disease. Ann Neurol 46, 860-866
89. LambertMP, BarlowAK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B,Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-6453
90. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297, 353-356 (Pubitemid 34790756)
91. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357
92. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimers disease. J Neurochem 95, 834-847 (Pubitemid 41567174)
93. Selkoe DJ (2008) Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimers disease. Handb Clin Neurol 89, 245-260
94. Lesne S, Kotilinek L, Ashe KH (2008) Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151, 745-749
95. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, Miesbauer L, Solomon L, Bartley D, Walter K, Johnson RW, Hajduk PJ, Olejniczak ET (2009) Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48, 1870-1877
96. King GD, Scott Turner R (2004) Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimers disease risk? Exp Neurol 185, 208-219 (Pubitemid 38084847)
97. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI (2002) The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23, 843-853 (Pubitemid 35217710)
98. Youdim KA, Martin A, Joseph JA (2000) Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 18, 383-399 (Pubitemid 30244351)
99. Farooqui A (2009) Neural membranes: a Pandoras box of lipid mediators in Hot topics in neural membrane lipidology. Springer, New York, pp. 1-36
100. Yang X, Sheng W, Sun GY, Lee JC (2011) Effects of fatty acid unsaturation numbers on membrane fluidity and alphasecretase- dependent amyloid precursor protein processing. Neurochem Int 58, 321-329
101. Eckert GP, Chang S, Eckmann J, Copanaki E, Hagl S, Hener U, Muller WE, Kogel D (2011) LiposomeincorporatedDHAincreases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim Biophys Acta 1808, 236-243
102. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42, 631-639
103. Goedert M, Klug A, Crowther RA (2006) Tau protein, the paired helical filament and Alzheimers disease. J Alzheimers Dis 9, 195-207 (Pubitemid 44253313)
104. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimers disease and related disorders. Nat Rev Neurosci 8, 663-672 (Pubitemid 47283144)
105. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85, 148-175
106. Julien C, Tremblay C, Bendjelloul F, Phivilay A, Coulombe MA, Emond V, Calon F (2008) Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J Neurosci Res 86, 2292-2302
107. Bertrand J, Senechal P, Zummo-SoucyM, PlouffeV, Leclerc N The formation of tau pathological phospho-epitopes in the axon is prevented by the dephosphorylation of selective sites in primary hippocampal neurons over-expressing human tau. J Neurochem 114, 1353-1367
108. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimers disease. Proc Natl Acad Sci U S A 101, 10804-10809 (Pubitemid 38955823)
109. Wang JZ, Grundke-Iqbal I, IqbalK(2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25, 59-68 (Pubitemid 46098893)
110. Li X, Lu F, Tian Q,YangY,Wang Q,Wang JZ (2006) Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. J Neural Transm 113, 93-102 (Pubitemid 41828960)
111. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119
112. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995 (Pubitemid 40675429)
113. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, Agullo JM, Perez M, Avila J, Guardia- Laguarta C, Clarimon J, Lleo A, Gomez-Isla T (2009) A novel GSK-3beta inhibitor reduces Alzheimers pathology and rescues neuronal loss in vivo. Neurobiol Dis 35, 359-367
114. Xiao J, Perry G, Troncoso J, Monteiro MJ (1996) alphacalcium- calmodulin-dependent kinase II is associated with paired helical filaments of Alzheimers disease. J Neuropathol Exp Neurol 55, 954-963 (Pubitemid 126449409)
115. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimers disease. Neurobiol Aging 25, 663-674 (Pubitemid 38686490)
116. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimers disease. Glia 58, 831-838
117. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimers disease. Proc Natl Acad Sci U S A 103, 5161-5166
118. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimers disease. J Neurosci 20, 5709-5714 (Pubitemid 30636898)
119. Ariel A, Serhan CN (2007) Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 28, 176-183 (Pubitemid 46467520)
120. Lalancette-Hebert M, Julien C, Cordeau P, Bohacek I,Weng YC, Calon F and Kriz J (2011) Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. Stroke, on-line Aug 18, 2011
121. Calder PC (2006) Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 75, 197-202 (Pubitemid 44292527)
122. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ (2008) The role of eicosanoids in the brain. Asia Pac J Clin Nutr 17(Suppl 1), 220-228
123. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA (1996) Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimers disease brain. Neurobiol Dis 3, 51-63 (Pubitemid 26145405)
124. Boudrault C, Bazinet RP, Kang JX, Ma DW (2010) Cyclooxygenase-2 and n-6 PUFA are lower and DHA is higher in the cortex of fat-1 mice. Neurochem Int 56, 585-589
125. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM (2008) Worldwide variation in the doubling time of Alzheimers disease incidence rates. Alzheimers Dement 4, 316-323
126. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkenstein HH, Evans DA (1995). Agespecific incidence of Alzheimers disease in a community population. JAMA 273, 1354-1359